Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tenofovir disoproxil fumarate

tenofovir disoproxil fumarate

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tenofovir disoproxil fumarate

21 trials tracked of tenofovir disoproxil fumarate: 11 in phase 3 or 4 and 4 with published results. The most-cited published study has 6953 citations.

21Trials tracked
11Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 6 Phase 3 5 Phase 2 8 Phase 1 1 Other / NA 1
  1. Phase 3 Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed · 6,953 cited
  2. Phase 3 Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand Completed · 282 cited
  3. Phase 4 Arresting Vertical Transmission of Hepatitis B Virus Completed · 55 cited
  4. Phase 4 A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Completed · 1 cited
  5. Phase 4 Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept Completed
  6. Phase 4 Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study Completed
Show 15 more trials
  1. Phase 4 Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis Completed
  2. Phase 4 A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection Completed
  3. Phase 3 A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment Completed
  4. Phase 3 PK of TAF and TDF for PrEP in Pregnant and Postpartum Women Completed
  5. Phase 3 NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission Completed
  6. Phase 2 Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Completed
  7. Phase 2 Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men Completed
  8. Phase 2 A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years Completed
  9. Phase 2 Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment Completed
  10. Phase 2 Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women Completed
  11. Phase 2 Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen Completed
  12. Phase 2 Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women Completed
  13. Phase 2 Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women Completed
  14. Phase 1 A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs Completed
  15. N/A Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults Completed

Showing the 21 most-cited and recently-updated of 21 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
F/TAF PrEP shows similar HIV incidence to F/TDF in cisgender women but noninferiority not proven
Infectious Disease RCT
F/TAF PrEP shows similar HIV incidence to F/TDF in cisgender women but noninferiority not proven PrEP pill F/TAF shows similar HIV prevention as F/TDF in women
This RCT in 1380 predominantly cisgender women in East and South Africa compared daily oral F/TAF vs F/TDF for HIV PrEP over 6 months. HIV i…
A study in African women found that a newer PrEP pill (F/TAF) prevented HIV at similar rates to the standard pill (F/TDF), but the study was…
Jun 1, 2026
Preplanned subanalysis shows comparable viral suppression rates for two dolutegravir-based regimens in antiretroviral-naive people with HIV at week 48
Infectious Disease RCT
Preplanned subanalysis shows comparable viral suppression rates for two dolutegravir-based regimens in antiretroviral-naive people with HIV at week 48 New HIV drug combo shows similar virus control to standard care in people with resistance markers
A preplanned subanalysis of a phase IV study compared dolutegravir plus lamivudine against dolutegravir plus tenofovir disoproxil fumarate w…
A specific HIV drug mix controlled the virus just as well as a standard mix in people with certain resistance markers, offering a potential …
Jun 1, 2026
Tenofovir Disoproxil Fumarate in Maternal ART Linked to Modest Creatinine Decline in HIV-Positive Women
Infectious Disease RCT
Tenofovir Disoproxil Fumarate in Maternal ART Linked to Modest Creatinine Decline in HIV-Positive Women Women on TDF-based HIV meds showed kidney changes compared to infant-only treatment
This randomized trial compared tenofovir disoproxil fumarate (TDF)-containing maternal antiretroviral therapy (ART) with infant nevirapine p…
Women taking TDF-based HIV meds had larger drops in kidney function than those on infant-only treatment, but calcium and phosphate levels st…
May 1, 2026
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months
Drug Pipeline Cohort
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months Switching HIV drugs showed similar metabolic changes over two years in this real-world study
This retrospective real-world study evaluated 326 virologically suppressed persons with HIV (PLWH) switching from efavirenz/tenofovir disopr…
Switching HIV drugs caused similar weight gain and metabolic shifts over two years, meaning lifestyle factors matter more than the specific …
Frontiers Apr 18, 2026
Cochrane review: injectable lenacapavir cuts HIV infections versus oral PrEP at 52 weeks
Infectious Disease Meta-analysis
Cochrane review: injectable lenacapavir cuts HIV infections versus oral PrEP at 52 weeks One Shot Saves You From HIV For Six Months
This Cochrane systematic review and meta-analysis of two randomised controlled trials (8660 participants) compared six-monthly subcutaneous …
A single shot under the skin protects against HIV for six months, solving the daily pill problem for millions at risk.
Apr 15, 2026